Immunomodulatory effects of nematode-microbiota interactions in cancer therapy

Among parasites, roundworms release substances that quietly reshape how the body's defences respond - a dance shaped by long evolution. One player, called p43 - also known as Tm-DLP-1 - (Trichuris muris Dorylaimia Lipid-carrying Protein-1), makes up nearly all of it. Scientists now see this protein not just as a worm tool but as something that can steer immune responses, possibly helping fight tumours. Here lies an exploration: how p43 alters immunity, teams up with gut microbes, and shows promise in early tests and trials against cancer. Beyond its role inside the parasite hauling lipids around, p43 works outside by grabbing tightly onto IL-13, a signal involved in fighting worms - and oddly enough - in feeding some cancers. Thanks to parts resembling the IL-13 receptor alpha-2 and sections like those found in thrombospondin, this protein binds IL-13 strongly while also attaching to sugar chains in the tissue scaffold, leaving pockets where immune behaviour shifts subtly. Despite strong results across several animal cancer models - slowed tumours, stronger CD8+ T cell attacks, weaker regulatory T cell activity - the path forward stays uncertain. Safety data in healthy humans come from trials using Trichuris suis ova, yet those with weakened immune systems face lingering risks. A molecule called p43/Tm-DLP-1 emerges here, not by chance, due to its ability to block IL-13 while shifting gut microbes. Still, progress demands more lab refinement, larger production methods, and human studies built with precision before any real impact can take hold.